Allergic reactions are usually mild or moderate, generally occur within the first 24 hours of an infusion, and include hives, swollen face, eyelids, lips, tongue, throat, or trouble breathing. There have been some serious allergic reactions reported in patients after receiving an infusion of ORENCIA.
There have been rare cases of certain kinds of cancer in patients receiving ORENCIA. The role of ORENCIA in the development of cancer is not known.
The more common side effects with ORENCIA are headache, upper respiratory tract infection, sore throat, and nausea.
Bristol-Myers Squibb Company is a global biopharmaceutical and related
health care products company whose mission is to extend and enhance human
(1) American College of Rheumatology, Patient Education, Rheumatoid
Arthritis. Available at
Accessed May 2006.
(2) 2007 Bristol-Myers Squibb Rheumatoid Arthritis Study, Update 3. GFK
Roper Public Affairs & Media. June 11, 2007.
(3) National Institute of Arthritis and Musculoskeletal and Skin Diseases.
National Institutes of Health. U.S. Department of Health and Human
Services. Rheumatoid Arthritis. May 2004.
(4) Lee DM and Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358:903-
(5) ORENCIA(R) (abatacept). Prescribing Information. Bristol-Myers Squibb.
Princeton, NJ 08543. March 2007.
|SOURCE Bristol-Myers Squibb|
Copyright©2008 PR Newswire.
All rights reserved